Skip to Content
Merck
CN

P8396

Piperacillin sodium salt

penicillin analog

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C23H26N5NaO7S
CAS Number:
Molecular Weight:
539.54
UNSPSC Code:
51282423
NACRES:
NA.85
PubChem Substance ID:
EC Number:
261-868-6
Beilstein/REAXYS Number:
5373920
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Piperacillin sodium salt, penicillin analog

InChI key

WCMIIGXFCMNQDS-IDYPWDAWSA-M

InChI

1S/C23H27N5O7S.Na/c1-4-26-10-11-27(19(32)18(26)31)22(35)25-13(12-8-6-5-7-9-12)16(29)24-14-17(30)28-15(21(33)34)23(2,3)36-20(14)28;/h5-9,13-15,20H,4,10-11H2,1-3H3,(H,24,29)(H,25,35)(H,33,34);/q;+1/p-1/t13-,14-,15+,20-;/m1./s1

SMILES string

[Na+].CCN1CCN(C(=O)N[C@@H](C(=O)N[C@H]2[C@H]3SC(C)(C)[C@@H](N3C2=O)C([O-])=O)c4ccccc4)C(=O)C1=O

form

powder

solubility

H2O: soluble 50 mg/mL

antibiotic activity spectrum

Gram-negative bacteria
Gram-positive bacteria

mode of action

cell wall synthesis | interferes

storage temp.

2-8°C

Quality Level

Looking for similar products? Visit Product Comparison Guide

Application

Piperacillin is a semisynthetic, broad-spectrum ureidopenicillin antibiotic. It is derived from ampicillin. It has been used in pharmacokinetic studies in order to optimize antimicrobial therapy in patients with sepsis. It is used to study piperacillin hypersensitivity reactions and to study multidrug-resistant organisms.

Biochem/physiol Actions

Piperacillin inhibits the last stage of bacterial cell wall synthesis by binding to certain penicillin-binding proteins (PBPs), which results in cell lysis. Cell lysis is mediated by bacterial cell wall autolytic enzymes. Piperacillin may interfere with autolysin inhibitors.

Other Notes

Keep container tightly closed in a dry and well-ventilated place.Keep in a dry place.

Packaging

1g,5g,10g

General description

Chemical structure: β-lactam

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

涉药品监管产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Zhiping Li et al.
European journal of clinical pharmacology, 69(6), 1223-1233 (2013-01-29)
To develop population pharmacokinetic (PK) models for piperacillin/tazobactam in neonates and infants of less than 2 months of age in order to determine the appropriate dosing regimen and provide a rational basis for the development of preliminary dosing guidelines suitable
N C Schaper et al.
Infection, 41(1), 175-186 (2012-11-28)
The aim was to compare the efficacy and safety of two antibiotic regimens in patients with diabetic foot infections (DFIs). Data of a subset of patients enrolled in the RELIEF trial with DFIs requiring surgery and antibiotics were evaluated retrospectively.
M A Zeitlinger et al.
The Journal of antimicrobial chemotherapy, 56(4), 703-708 (2005-08-27)
Pharmacokinetic (PK)/pharmacodynamic (PD) models have become increasingly important in optimizing antimicrobial therapy. This approach is highly recommended by regulatory authorities intending to force the evaluation of antimicrobial action at the site of infection. Clinical isolates of Pseudomonas aeruginosa and Staphylococcus
Jennifer A Pratt et al.
Pediatric blood & cancer, 61(2), 366-368 (2013-09-17)
Neutropenic fever is a common complication of myelosuppressive therapy in pediatric oncology patients. Piperacillin-tazobactam (PIP/TAZO) is a broad spectrum antibiotic used for empiric treatment of neutropenic fever. We describe four cases of suspected PIP/TAZO induced nephrotoxicity occurring in children with
William H Fissell
Advances in chronic kidney disease, 20(1), 85-93 (2012-12-26)
Acute kidney injury (AKI) is a common problem in hospitalized patients and is associated with significant morbidity and mortality. Two large trials showed no benefit from increased doses of renal replacement therapy (RRT) despite previous clinical data suggesting that increased

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service